COMP <GO>
ADVB vs BGLC // EV/EBITDA & P/E VALUATION
Advanced Biomed Inc. (NASDAQ) VS. BioNexus Gene Lab Corp (NASDAQ) • 15-METRIC TALLY: ADVB 2
— BGLC 2
■ METRIC PARITY
LAST: $2.64 (-11.41%) • MKT CAP: $4.4M
valuation
—
LAST: $0.98 (-7.79%) • MKT CAP: $2.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADVB VS. BGLC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADVB | BGLC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 14.60% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -9.10% | -35.00% | +25.90 | ADVB | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -39.90% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -40.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -21.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.12 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | BGLC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.4 | 24.5 | -4.13 | BGLC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.4M | $2.9M | $1.5M | ADVB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADVB REV | BGLC REV | ADVB GROSS % | BGLC GROSS % | ADVB FCF | BGLC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $7.4M | — | 14.6% | -$5.9M | -$1.9M |
| FY 2024 | $0 | $9.5M | — | 13.6% | -$2.2M | -$2.3M |
| FY 2023 | — | $9.8M | — | — | — | -$1.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADVB // BETA —
BGLC // BETA —